Jagsonpal Pharmaceuticals Limited

NSEI:JAGSNPHARM Stok Raporu

Piyasa değeri: ₹14.6b

Jagsonpal Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 0/4

Jagsonpal Pharmaceuticals CEO'su Manish Gupta, Jul2022 tarihinde atandı, in görev süresi 2.33 yıldır. in toplam yıllık tazminatı ₹ 26.70M olup, şirket hissesi ve opsiyonları dahil olmak üzere 100% maaş ve 0% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.29% ine doğrudan sahiptir ve bu hisseler ₹ 333.91M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.8 yıl ve 2.4 yıldır.

Anahtar bilgiler

Manish Gupta

İcra Kurulu Başkanı

₹26.7m

Toplam tazminat

CEO maaş yüzdesi100.0%
CEO görev süresi2.3yrs
CEO sahipliği2.3%
Yönetim ortalama görev süresi1.8yrs
Yönetim Kurulu ortalama görev süresi2.4yrs

Son yönetim güncellemeleri

Recent updates

Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

Oct 14
Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E

There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

May 27
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings

There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

Apr 30
There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Apr 05
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Feb 06
Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking

Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jul 29
Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

May 13
A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

Jul 05
Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?

A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jun 13
A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Apr 19
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting

Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Mar 21
Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?

Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

Feb 08
Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?

The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Jan 08
The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio

Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Dec 21
Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock

Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Nov 30
Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?

CEO Tazminat Analizi

Manish Gupta'un ücretlendirmesi Jagsonpal Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

₹243m

Jun 30 2024n/an/a

₹203m

Mar 31 2024₹27m₹27m

₹225m

Dec 31 2023n/an/a

₹245m

Sep 30 2023n/an/a

₹283m

Jun 30 2023n/an/a

₹313m

Mar 31 2023₹11m₹11m

₹267m

Tazminat ve Piyasa: Manish 'nin toplam tazminatı ($USD 317.52K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 179.47K ).

Tazminat ve Kazançlar: Manish şirketinin tazminatı %20'den fazla artarken, şirketin kazancı geçen yıl %20'den fazla düştü.


CEO

Manish Gupta (57 yo)

2.3yrs

Görev süresi

₹26,700,000

Tazminat

Mr. Manish Gupta serves as Non-Executive Director at Solara Active Pharma Sciences Ltd. since 2024. He serves as Operating Partner of pharmaceuticals at Convergent Finance LLP since joining the firm in Jul...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Manish Gupta
MD & Director2.3yrs₹26.70m2.29%
₹ 333.9m
Ashish Lakhotia
Chief Financial Officerless than a year₹790.00kVeri yok
Abhishek Joshi
Company Secretary & Compliance Officer1.8yrs₹890.00kVeri yok
Sudeep Paul
Vice President of Sales & Marketingno dataVeri yokVeri yok
Bharat Chugh
Assistant General Manager of Human Resourcesno dataVeri yokVeri yok

1.8yrs

Ortalama Görev Süresi

Deneyimli Yönetim: JAGSNPHARM 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Manish Gupta
MD & Director2.3yrs₹26.70m2.29%
₹ 333.9m
Harsha Raghavan
Non-Executive Chairman2.4yrsVeri yokVeri yok
Rajpal P. Kochhar
Chairman Emeritusno data₹6.81m4.58%
₹ 666.1m
Debasis Nandy
Independent Director2.4yrs₹1.10mVeri yok
Prithipal Kochhar
Non-Executive Director2.4yrsVeri yok0.39%
₹ 56.6m
Pallavi Gupta
Independent Director2.4yrs₹1.00mVeri yok
Radhika Dudhat
Independent Director2.4yrs₹900.00kVeri yok

2.4yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: JAGSNPHARM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.